DK2082745T3 - Kræftterapi med en parvovirus kombineret med kemoterapi - Google Patents
Kræftterapi med en parvovirus kombineret med kemoterapiInfo
- Publication number
- DK2082745T3 DK2082745T3 DK07025216.8T DK07025216T DK2082745T3 DK 2082745 T3 DK2082745 T3 DK 2082745T3 DK 07025216 T DK07025216 T DK 07025216T DK 2082745 T3 DK2082745 T3 DK 2082745T3
- Authority
- DK
- Denmark
- Prior art keywords
- parvovirus
- rat
- chemotherapy
- cancer therapy
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07025216A EP2082745B1 (en) | 2007-12-28 | 2007-12-28 | Cancer therapy with a parvovirus combined with chemotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2082745T3 true DK2082745T3 (da) | 2013-03-25 |
Family
ID=39415278
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07025216.8T DK2082745T3 (da) | 2007-12-28 | 2007-12-28 | Kræftterapi med en parvovirus kombineret med kemoterapi |
| DK08867912.1T DK2227240T3 (da) | 2007-12-28 | 2008-12-23 | Parvovirus-cancerterapi og kombination med kemoterapi |
| DK11003657.1T DK2431045T3 (da) | 2007-12-28 | 2008-12-23 | Bugspytkirtelkræftterapi med en parvovirus |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08867912.1T DK2227240T3 (da) | 2007-12-28 | 2008-12-23 | Parvovirus-cancerterapi og kombination med kemoterapi |
| DK11003657.1T DK2431045T3 (da) | 2007-12-28 | 2008-12-23 | Bugspytkirtelkræftterapi med en parvovirus |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8414883B2 (da) |
| EP (3) | EP2082745B1 (da) |
| JP (1) | JP5269096B2 (da) |
| AT (1) | ATE513552T1 (da) |
| CA (1) | CA2710928C (da) |
| DK (3) | DK2082745T3 (da) |
| ES (3) | ES2402138T3 (da) |
| PL (1) | PL2227240T3 (da) |
| PT (1) | PT2227240E (da) |
| WO (1) | WO2009083232A1 (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2266587A1 (en) * | 2009-06-04 | 2010-12-29 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Oncolytic virotherapy for prevention of tumor recurrence |
| CA2821034C (en) * | 2009-12-11 | 2017-12-05 | Niiki Pharma Inc. | Method of treating pancreatic cancer |
| EP2366398A1 (en) * | 2010-03-17 | 2011-09-21 | Deutsches Krebsforschungszentrum | Cancer therapy with a parvovirus combined with an HDAC inhibitor |
| EP2383577A1 (en) * | 2010-04-30 | 2011-11-02 | Deutsches Krebsforschungszentrum | Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy |
| EP2397542A1 (en) * | 2010-06-17 | 2011-12-21 | Deutsches Krebsforschungszentrum | Modified parvovirus having enhanced anti-tumour efficacy |
| EP2404609A1 (en) * | 2010-07-07 | 2012-01-11 | Deutsches Krebsforschungszentrum | Use of parvovirus for eliminating cancer stem cells (CSCs) |
| WO2012052158A2 (en) * | 2010-10-21 | 2012-04-26 | Deutsches Krebsforschungszentrum | Retargeting of rat parvovirus h-1pv to cancer cells through genetic engineering of its capsid |
| US20120166522A1 (en) * | 2010-12-27 | 2012-06-28 | Microsoft Corporation | Supporting intelligent user interface interactions |
| US20130129678A1 (en) * | 2011-11-17 | 2013-05-23 | Zahari Raykov | Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer |
| JP5689919B2 (ja) * | 2013-05-24 | 2015-03-25 | キヤノンアネルバ株式会社 | 情報処理装置、情報処理方法、コンピュータプログラムおよびコンピュータ可読メモリ媒体 |
| EP2829284A1 (en) | 2013-07-22 | 2015-01-28 | Deutsches Krebsforschungszentrum | Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor |
| EP3056216B1 (en) * | 2015-02-11 | 2017-02-01 | Deutsches Krebsforschungszentrum | Cancer therapy with a parvovirus combined with bevacizumab |
| EP3108892A1 (en) | 2015-06-23 | 2016-12-28 | Deutsches Krebsforschungszentrum | Parvovirus formulation for treating tumors |
| EP3225253A1 (en) | 2016-04-01 | 2017-10-04 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor |
| GB201608918D0 (en) * | 2016-05-20 | 2016-07-06 | Aslan Pharmaceuticals Pte Ltd | Method |
| EP3657172A1 (en) | 2018-11-22 | 2020-05-27 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Method for predicting the clinical response of oncolytic parvovirus h1 (h-1pv) treatment in a patient suspected of suffering from cancer by measuring the expression levels of laminins and/or galectins as biomarkers in a patient´s sample |
| US20240041833A1 (en) | 2020-12-21 | 2024-02-08 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Pharmaceutical combination product comprising a protoparvovirus and an antiviral benzimidazole and uses thereof for treating cancer |
| KR102617487B1 (ko) | 2021-04-14 | 2023-12-29 | 부산대학교 산학협력단 | 재조합 킬함 쥐 바이러스 (Kilham rat virus) 제조 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ336676A (en) * | 1997-01-24 | 2000-01-28 | Norsk Hydro As | Gemcitabine esters or amides useful as anti-cancer and anti-viral agents |
| DE19825620C2 (de) * | 1998-06-08 | 2002-12-12 | Deutsches Krebsforsch | Verwendung von adenoassoziierten Viren zur Senkung der radio- oder chemotherapieinduzierten Resistenz bei Krebspatienten |
| US20010044420A1 (en) * | 1999-03-19 | 2001-11-22 | Nielsen Loretta Lynn | Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms |
| DE19951795A1 (de) * | 1999-10-27 | 2001-05-10 | Knebel Doeberitz Magnus Von | Verwendung von Parvoviren zur Verbesserung des Allgemeinzustandes bei Tumorpatienten oder Patienten mit chronischen oder konsumierenden Erkrankungen |
| TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| US20050171036A1 (en) | 2002-03-26 | 2005-08-04 | Banyu Pharmaceutical Co., Ltd. | Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination |
| TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| US7179456B2 (en) * | 2003-04-30 | 2007-02-20 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Use of parvovirus for brain tumor therapy |
| US7186699B2 (en) * | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| WO2008043576A1 (en) * | 2006-10-13 | 2008-04-17 | Medigene Ag | Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer |
| EP2426142A3 (en) * | 2006-10-16 | 2012-06-13 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
-
2007
- 2007-12-28 DK DK07025216.8T patent/DK2082745T3/da active
- 2007-12-28 EP EP07025216A patent/EP2082745B1/en active Active
- 2007-12-28 ES ES07025216T patent/ES2402138T3/es active Active
-
2008
- 2008-12-23 ES ES08867912T patent/ES2368597T3/es active Active
- 2008-12-23 AT AT08867912T patent/ATE513552T1/de active
- 2008-12-23 EP EP08867912A patent/EP2227240B1/en active Active
- 2008-12-23 WO PCT/EP2008/011075 patent/WO2009083232A1/en active Application Filing
- 2008-12-23 JP JP2010540070A patent/JP5269096B2/ja active Active
- 2008-12-23 ES ES11003657T patent/ES2408600T3/es active Active
- 2008-12-23 EP EP11003657A patent/EP2431045B1/en active Active
- 2008-12-23 DK DK08867912.1T patent/DK2227240T3/da active
- 2008-12-23 CA CA2710928A patent/CA2710928C/en active Active
- 2008-12-23 US US12/810,457 patent/US8414883B2/en active Active
- 2008-12-23 DK DK11003657.1T patent/DK2431045T3/da active
- 2008-12-23 PL PL08867912T patent/PL2227240T3/pl unknown
- 2008-12-23 PT PT08867912T patent/PT2227240E/pt unknown
-
2013
- 2013-03-07 US US13/788,802 patent/US20140234261A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2227240A1 (en) | 2010-09-15 |
| DK2227240T3 (da) | 2011-09-26 |
| ES2402138T3 (es) | 2013-04-29 |
| JP5269096B2 (ja) | 2013-08-21 |
| ES2408600T3 (es) | 2013-06-21 |
| US20110020287A1 (en) | 2011-01-27 |
| ES2368597T3 (es) | 2011-11-18 |
| EP2227240B1 (en) | 2011-06-22 |
| CA2710928C (en) | 2015-10-06 |
| EP2431045A1 (en) | 2012-03-21 |
| EP2082745A1 (en) | 2009-07-29 |
| US8414883B2 (en) | 2013-04-09 |
| US20140234261A1 (en) | 2014-08-21 |
| PL2227240T3 (pl) | 2011-11-30 |
| WO2009083232A1 (en) | 2009-07-09 |
| EP2431045B1 (en) | 2013-03-06 |
| ATE513552T1 (de) | 2011-07-15 |
| PT2227240E (pt) | 2011-09-27 |
| JP2011507923A (ja) | 2011-03-10 |
| DK2431045T3 (da) | 2013-06-03 |
| EP2082745B1 (en) | 2012-12-19 |
| CA2710928A1 (en) | 2009-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2082745T3 (da) | Kræftterapi med en parvovirus kombineret med kemoterapi | |
| MX2010001650A (es) | Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales. | |
| UY29705A1 (es) | " inhibidores macrocíclicos del virus de la hepatitis c" | |
| HK1123733A1 (en) | Viral hepatitis treatment | |
| MX2012001592A (es) | Composicion para el tratamiento de la infección del virus de la hepatitis b. | |
| MX2007008457A (es) | Eter n, n, n'-trimetil-bis-(aminoetilico) y sus derivados como catalizadores para poliuretanos. | |
| WO2011008495A3 (en) | Arginase formulations and methods | |
| MX357423B (es) | Sistema de desecho de medicamento general. | |
| NZ620988A (en) | Method for purifying recombinant adamts13 and other proteins and compositions thereof | |
| EP2186830A4 (en) | POLYETHYLENE GLYCOL-MODIFIED ALPHA 2B INTERFERON AND PREPARATION METHOD AND APPLICATIONS THEREOF | |
| CL2008003267A1 (es) | Compuestos derivados de macrociclos fusionados con pirrolidina, inhibidores de la serina proteasa ns3; composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la hepatitis c. | |
| MX2010001416A (es) | Compuesto para el tratamiento de la hepatitis c. | |
| CY1108521T1 (el) | Παρασκευη αλδεσλευκινης για φαρμακευτικη χρηση | |
| CO6331470A2 (es) | Antogonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2 | |
| MX2013006170A (es) | Formulaciones virales liquidas. | |
| WO2010149283A3 (de) | Phenyloxy(thio)phenylamidbenzoxa(thia)zole | |
| ATE479439T1 (de) | Parvovirus mit cpg-angereichertem genom zur krebstherapie | |
| MX342907B (es) | El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus. | |
| MX2010007926A (es) | Derivados de beta-aminoacidos. | |
| MX2011012240A (es) | Compuestos heterociclicos antivirales. | |
| TW200621489A (en) | Colored polymer mixtures with amine compounds as UV-stabilizers | |
| MY151450A (en) | Prompt nucleic acid delivery carrier composition | |
| GB201008123D0 (en) | Novel compounds | |
| WO2012003030A3 (en) | Methods of identifying & using anti-viral compounds | |
| MX2010010060A (es) | Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados, heterociclicos y aromaticos. |